Castle Biosciences (CSTL) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Strategic focus and growth areas

• Concentrates on high unmet clinical needs, building or acquiring best-in-class diagnostic tests in dermatology, GI cancer, and mental health.

• Five main growth areas: three dermatology tests, one GI test, and one mental health test.

• Robust evidence database supports clinical adoption and payer reimbursement.

• Expansion of sales territories, especially for TissueCypher, to drive further market penetration.

• Ongoing investment in commercial structure and R&D to support pipeline and evidentiary development.

Product performance and clinical impact

• DecisionDx-Melanoma test has reached about 30% market penetration, with potential to double over the next several years.

• DecisionDx-SCC and TissueCypher tests provide significant clinical utility, improving treatment pathways and patient outcomes.

• Studies show use of these tests leads to improved survival and cost savings, including a $970 million annual Medicare savings from optimized radiation therapy.

• Test volumes have grown from 28,000 to 70,000 over three years, reflecting strong adoption.

• Expansion in GI sales force from 24 to 40 territories, with plans to reach 60-65, aims to accelerate TissueCypher adoption.

Financial performance and outlook

• Q2 revenue reached $87 million, with adjusted gross margins in the high 70s to low 80s.

• Operating cash flow and adjusted EBITDA have improved, with $25 million in positive operating cash flow in Q2.

• Company holds $260 million in cash, supporting ongoing commercial and R&D investments.

• Expects continued growth in test volumes and value from recent clinical studies throughout 2024.

• On track for cash flow positivity and profitability, with strong positioning for 2025 and beyond.